12 Article(s)
Pub. Date
#Total Relationship(s)
1 16969427 Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006 Aug 1
2 20571060 Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 2010 Sep 1 1
3 23369054 Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013 Feb 1
4 23478312 Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 2013 2
5 24121462 Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. FASEB J 2014 Jan 1
6 25275238 Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 2014 Jul 1
7 25674907 Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 2015 Jun 1
8 27456876 Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord 2016 Jul 2
9 27500463 Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex<sup>®</sup>. Acta Neurol Scand 2017 Apr 1
10 32256440 The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms. Front Neurol 2020 2
11 33425427 Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M<sup>pro</sup>) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study. Scientifica (Cairo) 2020 1
12 35582858 A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev Neurother 2022 Jun 1 1